Omalizumab: a review of its use in the treatment of allergic asthma
GL Plosker, SJ Keam - BioDrugs, 2008 - Springer
Omalizumab, a monoclonal antibody that targets circulating IgE, is approved as add-on
therapy for adult and adolescent patients with severe allergic asthma in the EU and …
therapy for adult and adolescent patients with severe allergic asthma in the EU and …
Omalizumab: a novel therapy for allergic asthma
LA Davis - Annals of Pharmacotherapy, 2004 - journals.sagepub.com
OBJECTIVE: To review the pharmacology, efficacy, and safety of omalizumab, focusing on
the treatment of allergic asthma. DATA SOURCES: A MEDLINE search (1966—November …
the treatment of allergic asthma. DATA SOURCES: A MEDLINE search (1966—November …
Omalizumab: a review of its use in the management of allergic asthma
LM Bang, GL Plosker - Treatments in respiratory medicine, 2004 - Springer
Omalizumab (Xolair®) is a humanized monoclonal antibody used in the treatment of
adolescent and adult patients with moderate to severe allergic asthma inadequately …
adolescent and adult patients with moderate to severe allergic asthma inadequately …
Update on optimal use of omalizumab in management of asthma
G Pelaia, L Gallelli, T Renda, P Romeo… - Journal of Asthma …, 2011 - Taylor & Francis
Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the
treatment of severe allergic asthma. This drug inhibits allergic responses by binding to …
treatment of severe allergic asthma. This drug inhibits allergic responses by binding to …
Omalizumab: overview of pharmacology and efficacy in asthma
DK Ledford - Expert opinion on biological therapy, 2009 - Taylor & Francis
Background: Omalizumab is a monoclonal, humanized antibody specific for the region of IgE
that binds to the high affinity IgE receptor on basophils and mast cells. Subcutaneous …
that binds to the high affinity IgE receptor on basophils and mast cells. Subcutaneous …
Omalizumab in asthma: an update on recent developments
IgE is central to the pathophysiology of allergic asthma. Omalizumab, a humanized anti-IgE
mAb, specifically binds free IgE and interrupts the allergic cascade by preventing binding of …
mAb, specifically binds free IgE and interrupts the allergic cascade by preventing binding of …
Omalizumab in the management of patients with allergic (IgE-mediated) asthma
T Sandström - Journal of asthma and allergy, 2009 - Taylor & Francis
Immunoglobulin E (IgE) is central to the pathophysiology of allergic asthma. Omalizumab, an
anti-IgE monoclonal antibody, binds to the FcɛRI binding site on free IgE. As a result …
anti-IgE monoclonal antibody, binds to the FcɛRI binding site on free IgE. As a result …
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
R Buhl, M Soler, J Matz, R Townley… - European …, 2002 - Eur Respiratory Soc
The ability of omalizumab, an anti-immnoglobulin‐E agent, to maintain long‐term disease
control in patients with moderate-to-severe allergic asthma was investigated in a 24‐week …
control in patients with moderate-to-severe allergic asthma was investigated in a 24‐week …
Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma
M Luu, M Bardou, P Bonniaud… - Expert Opinion on Drug …, 2016 - Taylor & Francis
Introduction: Omalizumab is a subcutaneously administrated monoclonal anti-IgE antibody
indicated in adults, adolescents and children 6 years of age and older with moderate to …
indicated in adults, adolescents and children 6 years of age and older with moderate to …
Omalizumab in the treatment of severe asthma: efficacy and current problems
G Pelaia, T Renda, P Romeo… - Therapeutic …, 2008 - journals.sagepub.com
Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the
treatment of severe allergic asthma. This drug inhibits allergic responses by binding to …
treatment of severe allergic asthma. This drug inhibits allergic responses by binding to …